39.25

7.30% 2.67

Avalyn Pharma Inc (AVLN)

Overview News Price History Discussions Forecast

Avalyn Pharma Inc stock is traded at $39.25, with a volume of 193.37K. It is up +7.30% in the last 24 hours and up +38.79% over the past month. Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Previous Close:

$36.58

Open:

$36.8

24h Volume:

193.37K

Relative Volume:

0.59

Market Cap:

$1.74B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+15.71%

1M Performance:

+38.79%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$35.07

$39.48

1-Week Range:

$32.84

$39.99

52-Week Range:

$24.15

$39.99

Avalyn Pharma Inc Stock (AVLN) Company Profile

Name

Avalyn Pharma Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(206) 707-0340

Address

105 W FIRST ST., BOSTON

Employee

Twitter

Next Earnings Date

2026-09-02

Latest SEC Filings

AVLN's Discussions on Twitter

Compare AVLN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVLN Avalyn Pharma Inc	39.25	1.66B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Avalyn Pharma Inc Stock (AVLN) Latest News

01:10 AM

Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen - MarketBeat

01:10 AM

Aug 14, 2026

Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma - Stock Titan

Aug 14, 2026

Aug 13, 2026

Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings - MarketBeat

Aug 13, 2026

AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 13, 2026

Aug 12, 2026

Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Share Price, AVLN Stock News, AVLN Share Price & Updates - Kalkine

Aug 12, 2026

Avalyn Pharma Q2 Results: EPS misses estimate by 22.64% - scanx.trade

Aug 12, 2026

Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings - MarketBeat

Aug 12, 2026

Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Nigeria

Aug 12, 2026

Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary - TradingView

Aug 12, 2026

Avalyn Pharma's Q2 Net Loss Widens - Yahoo Finance

Aug 12, 2026

Avalyn: Q2 Earnings Snapshot - Yahoo Finance

Aug 12, 2026

AVLN: Completed Phase 2b trial enrollment and secured $413.5M cash runway into 2029 - TradingView

Aug 12, 2026

AVLN: Net loss widened on higher R&D spend; IPO proceeds extend cash runway into 2029 - TradingView

Aug 12, 2026

Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029 - TradingView

Aug 12, 2026

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - marketscreener.com

Aug 12, 2026

Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Aug 12, 2026

Aug 10, 2026

Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews

Aug 10, 2026

Aug 09, 2026

Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent

Aug 09, 2026

Aug 07, 2026

Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week HighTime to Buy? - MarketBeat

Aug 07, 2026

Jul 28, 2026

Avalyn Pharma CEO Baranowski: Inhaled Drugs Cut Lung Function Decline to 0.4%, Opening a $42 Billion Market Oral Therapies Can't Reach - finance.biggo.com

Jul 28, 2026

Jul 27, 2026

Enterprise value to revenue forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView

Jul 20, 2026

Price to sales forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView

Jul 20, 2026

Price to book forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView

Jul 20, 2026

Jul 19, 2026